SCHEMBL3874145

SCHEMBL3874145

Cc1c(Cl)cccc1S(=O)(=O)NCc1cccc(C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.56
MRGPRX4 Q96LA9 2/20 0.53
WDR5 P61964 1/20 0.50
TP53 P04637 1/20 0.49
POLB P06746 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CA12 O43570 1/20 0.48
CA9 Q16790 1/20 0.48
MCL1 Q07820 1/20 0.47
HTR6 P50406 1/20 0.46
LMNA P02545 1/20 0.46
SLC12A2 P55011 1/20 0.46
SLC12A5 Q9H2X9 1/20 0.46
GLA P06280 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
CYP19A1 P11511 2/20 0.45
GAA P10253 1/20 0.45
AKR1C3 P42330 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3873274 0.88 FABP4 (0.49) FABP4MRGPRX4TP53POLBCYP19A1
SCHEMBL3876675 0.85 HSD11B1 (0.53) FABP4TP53TDP1HTR6LMNA
SCHEMBL3883349 0.84 MRGPRX4 (0.52) FABP4MRGPRX4WDR5TP53NR1H4
SCHEMBL3876258 0.83 HSD11B1 (0.56) L3MBTL1LMNA
SCHEMBL3872896 0.81 LMNA (0.52) TP53POLBLMNANR1H4GAA
SCHEMBL3872261 0.80 ALDH1A1 (0.56) POLBLMNA
SCHEMBL3884734 0.80 MAPT (0.51) FABP4POLBLMNA
SCHEMBL4176458 0.79 LMNA (0.57) MRGPRX4TP53TDP1LMNACYP19A1
SCHEMBL3883351 0.77 MRGPRX4 (0.52) MRGPRX4WDR5TP53LMNA
SCHEMBL5899510 0.77 ALDH1A1 (0.47) WDR5HTR6LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed
EP-1814846-A1 11BETA-HSD1 INHIBITORS Evotec AG (DE) 2007-08-08 EP disclosed
WO-2006048330-A1 11ΒΕΤΑ-HSD1 INHIBITORS EVOTEC AG (DE) 2006-05-11 WO disclosed
EP-1655283-A1 11beta-HSD1 Inhibitors Evotec OAI AG (DE) 2006-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 FABP4 1873/4885MRGPRX4 1361/4885WDR5 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.